[Inhibition by a 2-pyridyltetrahydrothiophene derivative (40749 RP) of gastric secretion stimulated by pentagastrin. Results in 30 duodenal ulcer patients].
The aim of this study was to investigate the effects of a new antisecretory compound (40749 RP) on the pentagastrin stimulated gastric secretion (6 micrograms.kg-1 b. w. h-1) in 30 patients with duodenal ulcer. The drug was administered directly into the gastric lumen. Four different doses were tested: 50 mg (7 patients), 100 mg (6 patients), 150 mg (8 patients), and 200 mg (9 patients). 40749 RP produced a dose-dependent inhibition of maximal acid secretion (p less than 0.001). Fifty per cent inhibition was obtained with a dose of 0.916 mg.kg-1 b. w. corresponding to a dose of 60 mg per day for a patient weighting 65 kg. The inhibitory effect resulted from a decrease in both volumes and H+ concentrations, the influence of the later being prevalent at high dosages. Peptic concentrations were not significantly decreased and inhibition of peptic secretion correlated only with the reduction of volumes. These results showed that 40749 RP is a potent antisecretory drug which could be of benefit in the treatment of peptic ulcer disease. With regard to the duration of action of 40749 RP, a 60 to 100 mg dose administered once a day at bedtime appeared to be optimal regimen for future therapeutic trials.
D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004381:Duodenal Ulcer / Q000378:metabolism*; D005260:Female; D005750:Gastric Juice / Q000378:metabolism*; D006801:Humans; D008297:Male; D010418:Pentagastrin; D013876:Thiophenes / Q000494:pharmacology*
D000897:Anti-Ulcer Agents; D013876:Thiophenes; C034498:RP 40749; D010418:Pentagastrin
Inhibition par un dérivé pyridyl-2 tétrahydrothiophène (40749 RP) de la sécrétion gastrique stimulée par la pentagastrine. Résultats chez 30 ulcéreux duodénaux.